NORD Chief Strategy Officer on Health Equity’s Vital…
With Rare Disease Day coming up on February 28th, one of the leading organizations dedicated to serving affected patients in the US, the National…
Tagged with NORD
New Drug Approvals in China in 2020
Writing in the February edition of DIA’s Global Forum magazine, Xu Wang of Novo Nordisk Pharma China and Xiaoxi Wang from the Shanghai Center for…
Building a Health Data Ecosystem in Switzerland
Although Switzerland is ahead of many of its competitors in Europe on levels of healthcare innovation, one potential stumbling block is access to and…
Steve Profit – General Manager, Novo Nordisk Taiwan
Novo Nordisk's Steve Profit outlines the progression of the group's strategy in Taiwan, how the affiliate works with the Taiwanese healthcare system…
PharmaBoardroom Most Read Interviews of 2020
The top 10 most-read interviews on PharmaBoardroom in 2020 represents the broad geographic scope we have had in the past year. From Mexico to Morocco…
Chinese Pharma Share Price Hit; Pfizer-LianBio Linkup; Novo’s…
The latest from Chinese pharma, including a drop in share prices for Chinese vaccine firms in the wake of successful COVID-19 trial results from…
Rare Disease Strategies in the Booming US Market
Rare disease – defined in the US as a disease with a maximum patient population of 200,000 – is perhaps the most salient issue at the nexus of…
Mads Stoustrup – VP & General Manager, Novo Nordisk…
Novo Nordisk Switzerland’s Mads Stoustrup introduces the affiliate’s remarkable process on bringing innovative diabetes and obesity treatments to…
Peter L. Saltonstall – President & CEO, National…
Ahead of the 2020 US National Organization for Rare Disorders (NORD)’s Rare Diseases and Orphan Products Breakthrough Summit, NORD president and CEO…
Philipp Maerz – Head of Northern Cluster & GM Norway,…
Philipp Maerz, the recently appointed head of Merck’s Nordic and Baltic operations and GM for Norway, outlines the challenges of taking on a new…
Nordics Pharma Snapshot 2020
A selection of data on the Nordic pharma markets (Denmark, Finland, Iceland, Norway, and Sweden), including market value, R&D spend, production,…
The Long Read: Belgium – The Multifaceted
Squirreled away in the lowlands of North West Europe and somewhat dwarfed by the mighty neighbouring pharmaceutical powerhouses of Germany and France,…
